NTLA
Intellia Therapeutics Inc
NASDAQ: NTLA · HEALTHCARE · BIOTECHNOLOGY
$13.48
+8.32% today
Updated 2026-04-30
Market cap
$1.48B
P/E ratio
—
P/S ratio
21.87x
EPS (TTM)
$-3.81
Dividend yield
—
52W range
$7 – $28
Volume
5.1M
Intellia Therapeutics Inc (NTLA) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
7 of 8
Last 8 quarters
Avg EPS surprise
+10.2%
Last 4 quarters
Revenue YoY growth
+78.8%
Most recent quarter
EPS YoY growth
+34.6%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-10.8%
Last 3 reports
Positive reaction rate
33%
1 of 3 quarters
Largest single-day move
-29.8%
2025-11-06
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-02-26 | $-0.83 | +13.5% | $13.42 | $13.78 | +2.7% |
| 2025-11-06 | $-0.92 | +8.9% | $13.57 | $9.52 | -29.8% |
| 2025-08-07 | $-0.98 | +4.9% | $11.37 | $10.79 | -5.1% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.96 | $-0.83 | +13.5% | $23.02M | +78.8% |
| 2025-09-30 | $-1.01 | $-0.92 | +8.9% | $13.78M | +51.3% |
| 2025-06-30 | $-1.03 | $-0.98 | +4.9% | $14.24M | +104.8% |
| 2025-03-31 | $-1.27 | $-1.10 | +13.5% | $16.63M | -42.5% |
| 2024-12-31 | $-1.32 | $-1.27 | +3.5% | $12.87M | -771.6% |
| 2024-09-30 | $-1.38 | $-1.34 | +2.9% | $9.11M | -24.0% |
| 2024-06-30 | $-1.23 | $-1.52 | -23.6% | $6.96M | -48.8% |
| 2024-03-31 | $-1.38 | $-1.12 | +18.8% | $28.93M | — |
| 2023-12-31 | $-1.45 | $-1.46 | -0.7% | $-1.92M | — |
| 2023-09-30 | $-1.50 | $-1.38 | +8.0% | $11.99M | — |
| 2023-06-30 | $-1.32 | $-1.40 | -6.1% | $13.59M | — |
Frequently asked questions
Has Intellia Therapeutics Inc beaten earnings estimates?
Intellia Therapeutics Inc has beaten Wall Street EPS estimates in 7 of its last 8 quarterly reports, with an average EPS surprise of +10.2% over the last 4 quarters.
How does NTLA stock react to earnings?
NTLA stock has moved an average of -10.8% in the trading day following earnings over its last 3 reports, with positive reactions in 33% of those quarters.
What is Intellia Therapeutics Inc's revenue growth rate?
Intellia Therapeutics Inc reported year-over-year revenue growth of +78.8% in its most recent quarter, with EPS growing +34.6% year-over-year.